Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elranatamab + dexamethasone
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
Elranatamab (PF-06863135) is a humanized bispecific monoclonal antibody that targets both B cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T cells. By binding to these two targets, elranatamab brings T cells into close proximity with myeloma cells, enabling targeted T-cell-mediated cytotoxicity against the cancer. Dexamethasone is a synthetic corticosteroid used for its anti-inflammatory and immunosuppressive properties, commonly included in multiple myeloma regimens to reduce inflammation and manage immune-related side effects. The combination of elranatamab and dexamethasone has been studied in clinical trials for relapsed or refractory multiple myeloma[3][6][8]. Elranatamab is developed by Pfizer.
- Other names
- BCMA-CD3 bispecific antibody + dexamethasone
02
Targets
GR (Glucocorticoid receptor)BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on elranatamab + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elranatamab + dexamethasone.